Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 8Neoplasms 7Colorectal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 5Breast Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Glioma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Hematologic Neoplasms 3

Interventions

belzutifan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × von Hippel-Lindau Disease × Clear all
NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03401788 2026-04-13

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
50 enrolled 1 FDA

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡